Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Clinical trial NCT02124746 · COMPLETED

Trial details

NCT number: NCT02124746
Sponsor: Sierra Oncology LLC - a GSK company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Polycythemia Vera Essential Thrombocythemia

Start date: 2014-04-30
Primary completion: 2018-12-06
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.